Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pearl Therapeutics

- PMLiVE

AstraZeneca signs for-profit agreements for its COVID-19 vaccine

The for-profit deals are aimed to ‘progressively transition the vaccine to modest profitability’ as COVID-19 moves from a pandemic to an endemic disease

- PMLiVE

AZ’s Imfinzi boosts survival in biliary tract cancer

Positive results for Imfimzi plus chemotherapy offer hope for patients with a rare and aggressive gastrointestinal cancer

- PMLiVE

Valneva COVID-19 vaccine more effective than AZ

Valneva will seek regulatory approval in the UK and European Union after its COVID-19 vaccine candidate performed well in phase 3 trials

- PMLiVE

AZ’s Imfinzi combination shows promise in liver cancer

Combining Imfinzi with experimental monoclonal antibody tremelimumab improved overall survival in patients with the most common form of liver cancer

- PMLiVE

Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death

The antibody is the only long-acting combination shown to both prevent and treat COVID-19

- PMLiVE

AstraZeneca requests Emergency Use Authorization from FDA for COVID-19 antibody

Phase 3 data shows the long-acting antibody combination produces a 77% reduction in the risk of developing symptomatic COVID-19

- PMLiVE

Janssen’s RSV vaccine provides high protection against respiratory infections

The phase 2b data showed the RSV vaccine provided 80% protection against lower respiratory infections in adults aged 65 and older

- PMLiVE

FDA grants Enhertu Breakthrough Therapy Designation in breast cancer

Phase 3 trial data presented at ESMO shows Enhertu significantly reduced the risk of disease progression or death

- PMLiVE

AZ buys Caelum Biosciences for $500m

After AstraZeneca’s Alexion acquires all remaining equity in Caelum next week it will 'advance and accelerate' ongoing clinical development

- PMLiVE

Lynparza significantly delays disease progression as first-line treatment in prostate cancer

New data show AstraZeneca and Merck‘s PARP inhibitor, Lynparza, delayed disease progression as a first-line treatment in advanced prostate cancer

- PMLiVE

AstraZeneca invests in RNA tech platform

AstraZeneca will support research using VaxEquity’s RNA platform then pay at least $195m for each candidate that enters its pipeline

- PMLiVE

AstraZeneca chooses Ireland for $360m manufacturing site

The next-generation facility will make small molecule active ingredients, future-proofing the company’s supply chain and boosting the Irish life sciences sector

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links